Mardi C. Dier
Net Worth
Last updated:
What is Mardi C. Dier net worth?
The estimated net worth of Ms. Mardi C. Dier is at least $3,673,370 as of 14 Oct 2022. She owns shares worth $1,994,181 as insider, has earned $813,789 from insider trading and has received compensation worth at least $865,400 in Ultragenyx Pharmaceutical Inc..
What is the salary of Mardi C. Dier?
Ms. Mardi C. Dier salary is $216,350 per year as Executive Vice President & Chief Financial Officer in Ultragenyx Pharmaceutical Inc..
How old is Mardi C. Dier?
Ms. Mardi C. Dier is 61 years old, born in 1964.
What stocks does Mardi C. Dier currently own?
As insider, Ms. Mardi C. Dier owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | Executive Vice President & Chief Financial Officer | 66,695 | $29.9 | $1,994,181 |
What does Ultragenyx Pharmaceutical Inc. do?
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Mardi C. Dier insider trading
Ultragenyx Pharmaceutical Inc.
Ms. Mardi C. Dier has made 6 insider trades between 2021-2022, according to the Form 4 filled with the SEC. Most recently she sold 1,629 units of RARE stock worth $65,421 on 14 Oct 2022.
The largest trade she's ever made was exercising 3,484 units of RARE stock on 12 Oct 2022. As of 14 Oct 2022 she still owns at least 66,695 units of RARE stock.
Ultragenyx Pharmaceutical key executives
Ultragenyx Pharmaceutical Inc. executives and other stock owners filed with the SEC:
- Dr. Camille L. Bedrosian M.D. (72) Chief Medical Officer & Executive Vice President
- Dr. Emil D. Kakkis M.D., Ph.D. (65) Pres, Chief Executive Officer & Director
- Mr. Erik Harris (55) Executive Vice President & Chief Commercial Officer
- Mr. John Richard Pinion II (59) Chief Quality Operations Officer & Executive Vice President of Translational Sciences
- Ms. Mardi C. Dier (61) Executive Vice President & Chief Financial Officer